udt-logo-verdana-white-3
  • About us
  • Investment focus
  • Team
  • Investment proposal
  • contact
  • en
  • nl
AdobeStock_98985434
  1. Home›
  2. News

News.

Read the latest news here.

Category
  • News
  • Press
  • Case
  • Event
Market
  • Aerospace
  • Agri & Food
  • Defense & Security
  • Energy
  • High-tech systems & Materials
  • Life sciences & Health
  • Smart industries
  • Water & Maritime
Latest
  • Latest
  • Oldest
1200x630-PW1200x630-PW
News

Demcon focal and high tech systems at SPIE Photonics West 2026

Read more
treatment brain diseases treatment brain diseases
Press

Groundbreaking technology for the treatment of neurological diseases

Curix, part of the Demcon group, is developing groundbreaking technology for the treatment of life-threatening and debilitating neurological diseases. This new technology makes it possible to temporarily open the blood-brain barrier, addressing one of the biggest challenges in neurology. With this technology, drugs for brain tumors and neurodegenerative conditions, such as Alzheimer's and Parkinson's disease, can be delivered more efficiently. The participation of Twinning Participaties allows Curix to develop an injector system suitable for initial clinical studies in humans. “Our ultimate goal is to contribute to the development of improved treatments for neurological diseases”, says Peter Frinking, managing director and chief scientific officer at Curix.

Read more
treatment brain diseases treatment brain diseases
Press

Groundbreaking technology for the treatment of neurological diseases

Curix, part of the Demcon group, is developing groundbreaking technology for the treatment of life-threatening and debilitating neurological diseases. This new technology makes it possible to temporarily open the blood-brain barrier, addressing one of the biggest challenges in neurology. With this technology, drugs for brain tumors and neurodegenerative conditions, such as Alzheimer's and Parkinson's disease, can be delivered more efficiently. The participation of Twinning Participaties allows Curix to develop an injector system suitable for initial clinical studies in humans. “Our ultimate goal is to contribute to the development of improved treatments for neurological diseases”, says Peter Frinking, managing director and chief scientific officer at Curix.

Read more
Demcon unmanned systems vessel on the waterDemcon unmanned systems vessel on the water
News

Demcon multiphysics featured in Siemens global showcase.

We’re proud to share that Siemens has highlighted Demcon multiphysics in their latest success story. The showcase demonstrates how our team accelerates maritime innovation by bringing advanced simulation in-house. Using Simcenter STAR-CCM+, we reduced design iteration time for uncrewed surface vessels to under two weeks, saving €10,000 per iteration and enabling rapid optimization for open-sea conditions. This approach not only speeds up development but also improves vessel efficiency and sustainability.

Read more
demcon-daan-berghorst-storydemcon-daan-berghorst-story
News

how an internship sparked Daan’s journey to becoming an engineer

What started as a simple internship ended up shaping the course of Daan’s education and career. During his secondary vocational education in mechatronics, Daan took an orientation internship at Demcon, working on prototyping. That experience became a turning point.

Read more
dus-rijkswaterstaat-usv-remo-1dus-rijkswaterstaat-usv-remo-1
Press

Rijkswaterstaat receives first DUS V1875 unmanned survey vessel from Demcon unmanned systems

Rijkswaterstaat has officially received its first DUS V1875 unmanned survey vessel (USV), named REMO 1, from Demcon unmanned systems, marking an important milestone in future-proofing their services. The handover took place during an official handover event organized by Rijkswaterstaat, where invited guests were shown a live demonstration of its advanced autonomous capabilities.

Read more
« ‹
12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849
› »
Page 4 of 49
udt-logo-verdana-white-3
About usInvestment focusTeamInvestment proposal

Contact us

send a message
cookie policyprivacy statement
© 2026 UDT. All rights reserved.